Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma
Specific inhibitors of HIF-2α have recently been approved for the treatment of ccRCC in VHL disease patients and have shown encouraging results in clinical trials for metastatic sporadic ccRCC. However, not all patients respond to therapy and pre-clinical and clinical studies indicate that intrinsic...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
25 September 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 19, Pages: 1-18 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13194801 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.3390/cancers13194801 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/13/19/4801 
|
| Verfasserangaben: | Rouven Hoefflin, Sabine Harlander, Behnaz A. Abhari, Asin Peighambari, Mojca Adlesic, Philipp Seidel, Kyra Zodel, Stefan Haug, Burulca Göcmen, Yong Li, Bernd Lahrmann, Niels Grabe, Danijela Heide, Melanie Boerries, Anna Köttgen, Mathias Heikenwalder and Ian J. Frew |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1817607383 | ||
| 003 | DE-627 | ||
| 005 | 20250109055752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220927s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13194801 |2 doi | |
| 035 | |a (DE-627)1817607383 | ||
| 035 | |a (DE-599)KXP1817607383 | ||
| 035 | |a (OCoLC)1361713981 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Höfflin, Rouven |d 1989- |e VerfasserIn |0 (DE-588)1081213825 |0 (DE-627)845695681 |0 (DE-576)454045824 |4 aut | |
| 245 | 1 | 0 | |a Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma |c Rouven Hoefflin, Sabine Harlander, Behnaz A. Abhari, Asin Peighambari, Mojca Adlesic, Philipp Seidel, Kyra Zodel, Stefan Haug, Burulca Göcmen, Yong Li, Bernd Lahrmann, Niels Grabe, Danijela Heide, Melanie Boerries, Anna Köttgen, Mathias Heikenwalder and Ian J. Frew |
| 246 | 3 | 0 | |a hif-2alpha |
| 246 | 3 | 3 | |a Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2 alpha inhibitor-resistant clear cell renal cell carcinoma |
| 264 | 1 | |c 25 September 2021 | |
| 300 | |a 18 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 25 September 2021 | ||
| 500 | |a Gesehen am 27.09.2022 | ||
| 520 | |a Specific inhibitors of HIF-2α have recently been approved for the treatment of ccRCC in VHL disease patients and have shown encouraging results in clinical trials for metastatic sporadic ccRCC. However, not all patients respond to therapy and pre-clinical and clinical studies indicate that intrinsic as well as acquired resistance mechanisms to HIF-2α inhibitors are likely to represent upcoming clinical challenges. It would be desirable to have additional therapeutic options for the treatment of HIF-2α inhibitor resistant ccRCCs. Here we investigated the effects on tumor growth and on the tumor microenvironment of three different direct and indirect HIF-α inhibitors, namely the HIF-2α-specific inhibitor PT2399, the dual HIF-1α/HIF-2α inhibitor Acriflavine, and the S1P signaling pathway inhibitor FTY720, in the autochthonous Vhl/Trp53/Rb1 mutant ccRCC mouse model and validated these findings in human ccRCC cell culture models. We show that FTY720 and Acriflavine exhibit therapeutic activity in several different settings of HIF-2α inhibitor resistance. We also identify that HIF-2α inhibition strongly suppresses T cell activation in ccRCC. These findings suggest prioritization of sphingosine pathway inhibitors for clinical testing in ccRCC patients and also suggest that HIF-2α inhibitors may inhibit anti-tumor immunity and might therefore be contraindicated for combination therapies with immune checkpoint inhibitors. | ||
| 650 | 4 | |a clear cell renal cell carcinoma | |
| 650 | 4 | |a HIF-2α resistance | |
| 650 | 4 | |a HIF-inhibitors | |
| 650 | 4 | |a sphingosine-pathway inhibition | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Harlander, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abhari, Behnaz |d 1981- |e VerfasserIn |0 (DE-588)1029304688 |0 (DE-627)733238955 |0 (DE-576)377199079 |4 aut | |
| 700 | 1 | |a Peighambari, Asin |e VerfasserIn |0 (DE-588)1216643326 |0 (DE-627)1727876474 |4 aut | |
| 700 | 1 | |a Adlesic, Mojca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seidel, Philipp |e VerfasserIn |0 (DE-588)1058653822 |0 (DE-627)797362975 |0 (DE-576)414801873 |4 aut | |
| 700 | 1 | |a Zodel, Kyra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haug, Stefan |e VerfasserIn |0 (DE-588)125522259X |0 (DE-627)1799308073 |4 aut | |
| 700 | 1 | |a Uluvar, Burulc̨a |e VerfasserIn |0 (DE-588)1242435247 |0 (DE-627)1772305979 |4 aut | |
| 700 | 1 | |8 1\p |a Li, Yong |e VerfasserIn |0 (DE-588)1228570728 |0 (DE-627)1750414384 |4 aut | |
| 700 | 1 | |a Lahrmann, Bernd |d 1982- |e VerfasserIn |0 (DE-588)1022879715 |0 (DE-627)717324710 |0 (DE-576)366112821 |4 aut | |
| 700 | 1 | |a Grabe, Niels |e VerfasserIn |0 (DE-588)123210615 |0 (DE-627)716920697 |0 (DE-576)364937602 |4 aut | |
| 700 | 1 | |a Heide, Danijela |e VerfasserIn |0 (DE-588)1160541647 |0 (DE-627)1023813084 |0 (DE-576)505986116 |4 aut | |
| 700 | 1 | |a Börries, Melanie |d 1971- |e VerfasserIn |0 (DE-588)129955493 |0 (DE-627)484980688 |0 (DE-576)297920618 |4 aut | |
| 700 | 1 | |a Köttgen, Anna |d 1974- |e VerfasserIn |0 (DE-588)123510333 |0 (DE-627)706326423 |0 (DE-576)178153028 |4 aut | |
| 700 | 1 | |a Heikenwälder, Mathias |d 1976- |e VerfasserIn |0 (DE-588)1024541045 |0 (DE-627)720089840 |0 (DE-576)368599299 |4 aut | |
| 700 | 1 | |a Frew, Ian |d 1976- |e VerfasserIn |0 (DE-588)1089675941 |0 (DE-627)853438234 |0 (DE-576)460077228 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 19, Artikel-ID 4801, Seite 1-18 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:19 |g elocationid:4801 |g pages:1-18 |g extent:18 |a Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13194801 |x Resolving-System |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/19/4801 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20220927 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1024541045 |a Heikenwälder, Mathias |m 1024541045:Heikenwälder, Mathias |d 910000 |d 911700 |e 910000PH1024541045 |e 911700PH1024541045 |k 0/910000/ |k 1/910000/911700/ |p 16 | ||
| 998 | |g 123210615 |a Grabe, Niels |m 123210615:Grabe, Niels |d 910000 |d 910100 |d 50000 |e 910000PG123210615 |e 910100PG123210615 |e 50000PG123210615 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 12 | ||
| 998 | |g 1022879715 |a Lahrmann, Bernd |m 1022879715:Lahrmann, Bernd |d 50000 |e 50000PL1022879715 |k 0/50000/ |p 11 | ||
| 999 | |a KXP-PPN1817607383 |e 4192418355 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 27.05.2020"],"pubHistory":["1.2009 -"],"language":["eng"],"recId":"614095670","id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinomaCancers","origin":[{"dateIssuedKey":"2009","publisherPlace":"Basel","dateIssuedDisp":"2009-","publisher":"MDPI"}],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Cancers","title":"Cancers"}],"part":{"volume":"13","text":"13(2021), 19, Artikel-ID 4801, Seite 1-18","extent":"18","issue":"19","pages":"1-18","year":"2021"}}],"title":[{"title":"Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma","title_sort":"Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2α inhibitor-resistant clear cell renal cell carcinoma"}],"physDesc":[{"extent":"18 S."}],"language":["eng"],"note":["Published: 25 September 2021","Gesehen am 27.09.2022"],"titleAlt":[{"title":"Therapeutic effects of inhibition of sphingosine-1-phosphate signaling in hif-2 alpha inhibitor-resistant clear cell renal cell carcinoma"}],"person":[{"given":"Rouven","display":"Höfflin, Rouven","family":"Höfflin","role":"aut"},{"family":"Harlander","role":"aut","display":"Harlander, Sabine","given":"Sabine"},{"given":"Behnaz","role":"aut","family":"Abhari","display":"Abhari, Behnaz"},{"display":"Peighambari, Asin","role":"aut","family":"Peighambari","given":"Asin"},{"display":"Adlesic, Mojca","role":"aut","family":"Adlesic","given":"Mojca"},{"display":"Seidel, Philipp","role":"aut","family":"Seidel","given":"Philipp"},{"given":"Kyra","display":"Zodel, Kyra","family":"Zodel","role":"aut"},{"given":"Stefan","display":"Haug, Stefan","family":"Haug","role":"aut"},{"given":"Burulc̨a","display":"Uluvar, Burulc̨a","family":"Uluvar","role":"aut"},{"display":"Li, Yong","family":"Li","role":"aut","given":"Yong"},{"given":"Bernd","display":"Lahrmann, Bernd","role":"aut","family":"Lahrmann"},{"given":"Niels","display":"Grabe, Niels","role":"aut","family":"Grabe"},{"display":"Heide, Danijela","role":"aut","family":"Heide","given":"Danijela"},{"family":"Börries","role":"aut","display":"Börries, Melanie","given":"Melanie"},{"given":"Anna","display":"Köttgen, Anna","role":"aut","family":"Köttgen"},{"given":"Mathias","display":"Heikenwälder, Mathias","family":"Heikenwälder","role":"aut"},{"given":"Ian","family":"Frew","role":"aut","display":"Frew, Ian"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.3390/cancers13194801"],"eki":["1817607383"]},"recId":"1817607383","name":{"displayForm":["Rouven Hoefflin, Sabine Harlander, Behnaz A. Abhari, Asin Peighambari, Mojca Adlesic, Philipp Seidel, Kyra Zodel, Stefan Haug, Burulca Göcmen, Yong Li, Bernd Lahrmann, Niels Grabe, Danijela Heide, Melanie Boerries, Anna Köttgen, Mathias Heikenwalder and Ian J. Frew"]},"origin":[{"dateIssuedDisp":"25 September 2021","dateIssuedKey":"2021"}]} | ||
| SRT | |a HOEFFLINROTHERAPEUTI2520 | ||